Current Report Filing (8-k)
March 13 2020 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 13, 2020
Aclaris Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37581
|
|
46-0571712
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
640 Lee Road, Suite 200
Wayne, PA 19087
(Address of principal executive offices,
including zip code)
(484) 324-7933
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of Each Class:
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange on which Registered
|
Common Stock, $0.00001 par value
|
|
ACRS
|
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant
is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. þ
Item 1.01 — Entry into a Material Definitive Agreement
On March 13, 2020, Aclaris Therapeutics, Inc.
(the “Company”) entered into an Open Market Sale Agreement (the “Agreement”) with Jefferies LLC (“Jefferies”)
under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.00001
per share (the “Common Stock”), having an aggregate offering price of up to $25,000,000 through Jefferies as its sales
agent. The issuance and sale, if any, of Common Stock by the Company under the Agreement is subject to the effectiveness of the
Company’s registration statement on Form S-3, to be filed with the Securities and Exchange Commission on March 13, 2020.
The Company makes no assurances as to if or whether the registration statement will become effective or, if it does become effective,
as to the continued effectiveness of the registration statement.
Jefferies may sell the Common Stock by
any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities
Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the Common Stock from time to time, based
upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company
may impose). The Company will pay Jefferies a commission equal to three percent (3.0%) of the gross sales proceeds of any Common
Stock sold through Jefferies under the Agreement. The Company has provided customary representations, warranties and covenants
and the parties have agreed to customary indemnification rights.
The Company is not obligated to make any
sales of Common Stock under the Agreement. The offering of shares of Common Stock pursuant to the Agreement will terminate upon
the earlier of (i) the sale of all Common Stock subject to the Agreement or (ii) termination of the Agreement in accordance
with its terms.
The foregoing description of the Agreement
is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith
as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K shall
not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any
offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
ACLARIS THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Frank Ruffo
|
Date: March 13, 2020
|
|
Frank Ruffo
Chief Financial Officer
|
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024